Glioblastoma’s Internal Clock: Timing Treatments May Hold the Key to Improved Outcomes
Glioblastoma, a deadly and aggressive brain cancer, appears to have an internal clock that synchronizes with the body’s natural rhythms. This discovery opens up exciting new possibilities for personalized treatment strategies that leverage the timing of therapies.
A groundbreaking study published in Cancer Cell by researchers at Washington University in St. Louis reveals that glioblastoma tumors align their growth with the daily release of steroid hormones like cortisol.
When researchers disrupted this synchronization by resetting the host’s circadian rhythms, they observed a dramatic slowdown in tumor growth.
Understanding the Clock Connection
Our bodies operate on a natural 24-hour cycle called the circadian rhythm, influenced by a central clock in the brain. This internal clock dictates everything from sleep-wake cycles and hormone release to body temperature and metabolism. Previously, researchers believed this rhythmic system was limited to healthy cells. This groundbreaking study reveals that glioblastoma takes advantage of this system to better thrive.
The research uncovered that glioblastoma cells utilize glucocorticoids, a type of steroid hormone surging before waking, to synchronize their own internal clock. This synchrony allows the tumor to leverage these hormones for growth.
“Our findings show that glioblastoma cells are absolutely following the same biological clock as their host,” said Erik D. Herzog, PhD, lead author of the study. “They’re taking advantage of the rhythmic release of these hormones to dictate their own growth and potentially become more aggressive.”
Timing Therapy: A Revolutionary Approach
The study’s findings have significant implications for how glioblastoma is treated in the future. Drugs like dexamethasone (DEX), a common treatment for brain swelling after surgery and radiation, have shown mixed results based on when they are administered. The study suggests that administering DEX in the morning could actually promote tumor growth while giving it in the evening could suppress it.
Professor Joshua Rubin, MD, PhD, a co-author of the study, emphasized the importance of these findings for personalized treatment: “This study suggests that timing is an essential variable when it comes to cancer treatments. We must move away from a ‘one-size-fits-all’ approach and consider individual patient circadian rhythms when deciding when to administer therapies.”
“This research has the potential to shift our whole approach to cancer treatment, shifting from a focus on drugs to a focus on timing,” concluded Herzog.
Learn More About Circadian Rhythms and Cancer Therapies
To stay updated on the latest advancements in cancer research and personalized medicine, visit the Neuroscience News website.